Tetsuya Taguchi

Tetsuya Taguchi

Auto-generated profile, based on publicly available information

Tetsuya Taguchi

Department of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2020 in Cancers
Verified
Journal Article
Open access
PDF file
KMKeiko Miyamoto
Keiko Miyamoto
MWMotoki Watanabe
Motoki Watanabe
BSBoku Shogen
Boku Shogen
MSMamiko Sukeno
Mamiko Sukeno
MMMie Morita
Mie Morita
TSToshiyuki Sakai
Toshiyuki Sakai
As histone deacetylase inhibitors (HDACIs) have limited efficacy against solid tumors, we investigated whether and how oxidative stress is involved in sensitivity to HDACIs to develop a novel therapeutic option of HDACIs treatment. We first tested whether a reduction of the antioxidant glutathione (GSH) by glutamine deprivation affects sensitivity to a commercially available HDACI vorinostat and reactive oxygen species (ROS) accumulation. Next we investigated the relationship between a glutamate-cystine transporter xCT and the efficacy of vorinostat using siRNA of xCT and bioinformatic analyses. Finally, we verified the combinatory effects of vorinostat and the xCT inhibitor salazosulfapyridine (SASP) on ROS accumulation, cell death induction, and colony formation. Glutamine deprivation increased vorinostat-mediated cell death with ROS accumulation. Genetic ablation of xCT improved the efficacy of vorinostat, consistent with the results of public data analyses demonstrating that xCT expressions positively correlate with insensitivity to HDACIs in many types of cancer cell lines. Vorinostat caused ROS accumulation when combined with SASP, possibly resulting in synergistic ferroptosis. Our study provides a novel mechanistic insight into the mechanism underlying sensitivity to HDACIs involving xCT, suggesting xCT to be a promising predictive marker of HDACIs and rationalizing combinatory therapy of HDACIs with xCT inhibitors to induce ferroptosis.

1 October 2018 in Journal of Pain Research
Verified
Journal Article
Open access
PDF file
AOAkiko Okamoto
Akiko Okamoto
MYMasaki Yamasaki
Masaki Yamasaki
IYIsao Yokota
Isao Yokota
MMMaiko Mori
Maiko Mori
MMMegumi Matsuda
Megumi Matsuda
FAfumimasa amaya
fumimasa amaya
Purpose: Predictive value and accuracy of the acute pain trajectory were compared with those of pain intensity at 1 day after the surgery for pain prevalence at 6 months after the surgery. Materials and methods: Female patients scheduled for breast cancer surgery were eligible for this study. Patients were questioned about pain intensity daily during the 7 days after surgery. Presence of pain, its location, and intensity as well as the Japanese version of the quality of the recovery-40 (QOR-40) were determined in an interview prior to and at 6 months after the surgery. Acute pain trajectory was determined by a group-based trajectory modeling analysis that was based on the pain intensity at 1–7 days after surgery. Predictive value of the acute pain trajectory for the presence of pain at 6 months after the surgery was assessed by a logistic regression model. The predictive value was compared with pain intensity at 1 day after the surgery. Results: A total of 123 participants completed the 6-month follow-up. The three-cluster model (mild, moderate, and severe pain) was considered to be the most statistically appropriate model for the acute pain trajectory. After 6 months, 51.2% and 8.9% of participants reported pain and severe pain, respectively. Presence of pain at 6 months after the surgery was associated with poor recovery. The severe pain cluster was significantly associated with the presence of pain at 6 months after the surgery (adjusted odds ratio, 9.40; P<0.001 vs mild pain cluster). Conclusion: Classification of patients according to the acute pain trajectory, when compared with the classification according to pain intensity at 1 day after the surgery, made it possible to predict with better precision those patients who will develop persistent postsurgical pain.

4 February 2012 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
STShunji Takahashi
Shunji Takahashi
TITakuji Iwase
Takuji Iwase
NKNorio Kohno
Norio Kohno
TITakashi Ishikawa
Takashi Ishikawa
TTTetsuya Taguchi
Tetsuya Taguchi
SNShinzaburo Noguchi
Shinzaburo Noguchi

1 December 1997 in Breast Cancer
Verified
Journal Article
Closed access
PDF file
FTFumine Tsukamoto
Fumine Tsukamoto
ESEiichi Shiba
Eiichi Shiba
TTTetsuya Taguchi
Tetsuya Taguchi
TSTakuji Sugimoto
Takuji Sugimoto
TWTaro Watanabe
Taro Watanabe
SAShin-Ichiro Ai
Shin-Ichiro Ai

6 February 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YKYuko Kanbayashi
Yuko Kanbayashi
Takeshi IshikawaTakeshi Ishikawa
Takeshi Ishikawa
YTYusuke Tabuchi
Yusuke Tabuchi
KSKoichi Sakaguchi
Koichi Sakaguchi
YOYoshimi Ouchi
Yoshimi Ouchi
TTTetsuya Taguchi
Tetsuya Taguchi
The development of proteinuria restricts the dose of anti-angiogenic agents, thereby reducing their efficacy. Thus, this retrospective study was undertaken to identify predictive factors of the development of angiogenesis inhibitor-induced proteinuria, and to elucidate if there is a difference in the likelihood of proteinuria among anti-angiogenic agents or cancer types, to help guide future strategies to improve the safety, efficacy, and quality of life of patients receiving chemotherapy. Between April 2014 and February 2019, 124 cancer patients at our outpatient chemotherapy center who were receiving chemotherapy with bevacizumab, ramucirumab, or aflibercept were enrolled. Variables related to the development of proteinuria were extracted from the patients’ clinical records and used for regression analysis. The level of the proteinuria was evaluated based on CTCAE version 5. Multivariate ordered logistic regression analysis was performed to identify predictive factors for the development of proteinuria. The Wilcoxon/Kruskal-Wallis test was used to identify significant differences between groups. Significant factors identified included systolic blood pressure (SBP) [odds ratio (OR) = 1.031, 95% confidence interval (CI) = 1.005–1.058; P = 0.0197], number of cycles (OR = 1.049, 95% CI = 1.018–1.082; P = 0.0019), and calcium channel blocker use (OR = 2.589, 95% CI = 1.090–6.146; P = 0.0311). There was no difference among the three anti-angiogenic agents (P = 0.4969) or among cancer types (P = 0.2726) in the likelihood of proteinuria. In conclusion, SBP, number of cycles, and calcium channel blocker use were identified as significant predictors of the development of angiogenesis inhibitor-induced proteinuria. There was no difference among the three anti-angiogenic agents or among cancer types.

16 January 2012 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
NMNaruhiko Mizuta
Naruhiko Mizuta
KSKoichi Sakaguchi
Koichi Sakaguchi
MMMitsuhiko Mizuta
Mitsuhiko Mizuta
AIAya Imai
Aya Imai
KNKatsuhiko Nakatsukasa
Katsuhiko Nakatsukasa
TTTetsuya Taguchi
Tetsuya Taguchi
Myoid hamartomas of the breast are extremely rare breast lesions, with a poorly understood pathogenesis. We describe the case of a 38-year-old premenopausal woman who presenting with a mass in the left breast. Mammography revealed an oval mass that was partly indistinct, and ultrasonography showed a hypoechoic mass with a slightly irregular margin. Bilateral breast dynamic magnetic resonance imaging was performed for a more detailed evaluation. The images showed rapid initial enhancement and a microlobulated margin. Because the suspicion of malignancy was strong at that time, core needle biopsy was performed. Histologically, the tumor was identified as fibroadenoma. A case of myoid hamartoma of the breast that proved difficult to diagnose is reported, and discussed with reference to the literature.